<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">Endothelial dysfunction</z:e> reflects an imbalance of <z:chebi fb="1" ids="35620">vasodilators</z:chebi> and vasoconstrictors </plain></SENT>
<SENT sid="1" pm="."><plain>Endogenous endothelin activity seems to be increased in human <z:hpo ids='HP_0001513'>obesity</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and cellular studies suggest that this factor may itself reduce bioavailable nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) </plain></SENT>
<SENT sid="2" pm="."><plain>We studied 20 lean, 20 <z:mp ids='MP_0001261'>obese</z:mp>, and 14 type 2 diabetic individuals under three protocols, measuring leg vascular responses to intra-arterial infusions of NG-monomethyl-l-arginine (l-NMMA; an inhibitor of NO synthase) alone or in combination with BQ123 (an <z:chebi fb="68" ids="48706">antagonist</z:chebi> of type A endothelin receptors) or phentolamine (used as a control <z:chebi fb="1" ids="35620">vasodilator</z:chebi>) </plain></SENT>
<SENT sid="3" pm="."><plain>NO synthase inhibition alone (study 1) produced an approximately 40% increase in leg vascular resistance (LVR) in <z:hpo ids='HP_0000001'>all</z:hpo> three participant groups, which was not statistically different across groups (increase in LVR: lean, 135 +/- 28; <z:mp ids='MP_0001261'>obese</z:mp>, 140 +/- 32; type 2 diabetic, 184 +/- 51 units; NS) </plain></SENT>
<SENT sid="4" pm="."><plain>By design, BQ123 at the infused rate of 3 micromol/min produced equivalent approximately 35% reductions in LVR across groups </plain></SENT>
<SENT sid="5" pm="."><plain>The subsequent addition of l-NMMA produced a greater increase in LVR among <z:mp ids='MP_0001261'>obese</z:mp> participants than lean or type 2 diabetic participants (study 2: lean, 182 +/- 48; <z:mp ids='MP_0001261'>obese</z:mp>, 311 +/- 66; type 2 diabetic, 186 +/- 40; P = 0.07) </plain></SENT>
<SENT sid="6" pm="."><plain>Compared with study 1, the effect of l-NMMA was magnified by BQ123 in <z:mp ids='MP_0001261'>obese</z:mp> participants but not in lean or type 2 diabetic participants (P = 0.005, study 1 vs. 2; P = 0.03 for group effect) </plain></SENT>
<SENT sid="7" pm="."><plain>Phentolamine (75 mg/min) produced vasodilation in <z:mp ids='MP_0001261'>obese</z:mp> participants comparable to that seen with BQ123 but failed to augment the <z:chebi fb="0" ids="28229">L-NMMA</z:chebi> response </plain></SENT>
<SENT sid="8" pm="."><plain>Endothelin antagonism unmasks or augments NO synthesis capacity in <z:mp ids='MP_0001261'>obese</z:mp> but not type 2 diabetic participants </plain></SENT>
<SENT sid="9" pm="."><plain>This suggests that impaired NO bioavailability as a result of endogenous endothelin may contribute to <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> in <z:hpo ids='HP_0001513'>obesity</z:hpo>, in addition to direct vasoconstrictor effects of endothelin </plain></SENT>
<SENT sid="10" pm="."><plain>In contrast, endothelin antagonism alone is insufficient to restore impaired NO bioavailability in <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>